HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination

Antiviral Research

Volumn 36, Issue 3, 1997, Pages 179-189

  Yusa, Keisuke ^a   Kavlick, Mark F ^a   Kosalaraksa, Pope ^a   Mitsuya, Hiroaki ^a  

^a Division of Clinical Sciences   (United States)

Author keywords

Antiviral drugs; HIV 1; Homologous recombination; Resistance

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; KYNOSTATIN 272; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; GENETIC ANALYSIS; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS GENOME; VIRUS MUTANT; VIRUS MUTATION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE, TRANSFORMED; COS CELLS; DIDANOSINE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTAGENESIS; OLIGOPEPTIDES; POLYMERASE CHAIN REACTION; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; TRANSFECTION; VIRUS REPLICATION; ZALCITABINE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031452514     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00053-3     Document Type: Article

References (38)

1. Anderson, B.D., Kageyama, S., Ueno, T., Mitsuya, H., 1994. In vitro induction of HIV-1 with reduced sensitivity to HIV protease inhibitors, KNI-227 and KNI-272, pp. 60. Tenth International Conference on AIDS, August 7-12, Yokohama, Japan.
2. Bebenek K., Abbotts J., Roberts J.D., Wilson S.H., Kunkel T.A. Specificity and mechanisms of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J. Biol. Chem. 262:1989;16948-16956.
3. Brown, A.J.L., Simmonds, P., 1995. Sequence analysis of virus variability based on the polymerase chain reaction PCR. In: J. Karn (Ed.), HIV Virology and Immunology Vol. 1, Oxford University Press, IRL Press, Oxford, pp. 161-188.
4. Coffin, J.M., 1996. Retroviridae: The viruses and their replication. In: B.N. Fields, D.M. Knipe, P.M. Howley (Eds.), Fields Virology. 3rd ed. Lipponcott-Raven Publishers, Philadelphia 2, pp. 1767-1847.
5. D'Aquila R.T., Johnson V.A., Welles S.L., Japour A.J., Kuritzkes D.R., DeGruttola V., Reichelderfer P.S., Coombs R.W., Crumpacker C.S., Kahn J.O., Richman D.D. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Int. Med. 122:1995;401-408.
6. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:1994;155-169.
7. Frohman, M.A., Martin, G.R., 1990. Detection of homologous recombinants. In: A.A. Innis, D.H. Gelfand, J.J. Sninsky, T.J. White, T.J., (Eds.), PCR Protocols. Academic Press Limited, London.
8. Gu Z., Fletcher R.S., Arts E.J., Wainberg M.A., Parniak M.A. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:1994;28118-28122.
9. Gu Z., Gao Q., Faust E.A., Wainberg M.A. Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J. Gen. Virol. 76:1995;2601-2605.
10. Hammer S.M., Katzenstein D.A., Hughes M.D., Gundacker H., Schooley R.T., Haubrich R.H., Henry W.K., Lederman M.M., Phair J.P., Niu M., Hirsch M.S., Merigan T.C. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 335:1996;1081-1090.
11. Hu W.S., Temin H.M. Genetic sequence of packaging two RNA genomes in one retroviral particle; pseudodiploidy and high rate of genetic recombination. Proc. Natl. Acad. Sci. U.S.A. 87:1990;1556-1560.
12. Kageyama S., Mimoto T., Murakawa Y., Nomizu M., Ford H. Jr., Shirasaka T., Gulnik S., Erickson J., Takada K., Hayashi H., Broder S., Kiso Y., Mitsuya H. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 37:1993;810-817.
13. Katzenstein D.A., Hammer S.M., Hughes M.D., Gundacker H., Jackson J.B., Fiscus S., Rasheed S., Elbeik T., Reichman R., Japour A., Merigan T.C., Hirsch M.S. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200-500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N. Engl. J. Med. 335:1996;1091-1098.
14. Kellam P., Larder B.A. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69:1995;669-674.
15. Kojima E., Shirasaka T., Anderson B.D., Chokekijchai S., Steinberg S.M., Broder S., Yarchoan R., Mitsuya H. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J. Infect. Dis. 171:1995;1152-1158.
16. Kozal M.J., Shafer R.W., Winters M.A., Katzenstein D.A., Merigan T.C. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:1993;526-532.
17. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
18. Larder B.A., Kellam P., Kemp S.D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature. 365:1993;451-453.
19. Maeda, Y., Mitsuya H., 1996. Emergence of multi-dideoxynucleoside-resistant HIV-1 in patients receiving long-term combination therapy with dideoxynucleosides. Fifth International Workshop, July 3-6, Whistler, Canada, pp. 40.
20. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:1995;5087-5094.
21. Meyerhans A., Vartanian J.P., Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res. 18:1990;1687-1691.
22. Mimoto T., Imai J., Kisanuki S., Enomoto H., Hattori N., Akaji K., Kiso Y. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenyl-norstatine. Chem. Pharm. Bull. 40:1992;2251-2253.
23. Montaner J.S.G., Singer J., Schechter M.T., Raboud J.M., Wainberg M.A. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicentre Canadian AZT trial. AIDS. 7:1993;189-196.
24. Moutouh L., Corbeil J., Richman D.D. Recombination leads to the rapid emergence of HIV-1 dually resistant mutations umder selective drug pressure. Proc. Natl. Acad. Sci. U.S.A. 93:1996;6106-6111.
25. Preston B.D., Poiesz B.J., Loeb L.A. Fidelity of HIV-1 reverse transcriptase. Science. 242:1988;1168-1171.
26. Richman D.D. HIV drug resistance. Ann. Rev. Pharmacol. Toxicol. 33:1993;149-164.
27. Richman D.D., Shih C.K., Lowry I., Rose J., Prodanovich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 88:1991;11241-11243.
28. Richman, D.D., Johnson, D.L., Mayor, T., Shirasaka, T., O'Brien, M.C., Mitsuya, H., 1993b. Current Protocol in Immunology. In: Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (Eds.), Wiley Interscience, Baltimore, MD. pp. 12.9.1-12.9.21.
29. Roberts J.D., Bebenek K., Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science. 242:1988;1171-1173.
30. Shafer R.W., Kozal M.J., Winters M.A., Iversen A.K.N., Katzenstein D.A., Ragni M.V., Meyer III W.A., Gupta P., Rasheed S., Coombs R., Katzman M., Fiscus S., Merigan T.C. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:1994;722-729.
31. Shirasaka T., Yarchoan R., O'Brien M.C., Husson R.N., Anderson B.D., Kojima E., Shimada T., Broder S., Mitsuya H. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. U.S.A. 90:1993;562-566.
32. Shirasaka T., Kavlick M.F., Ueno T., Gao W.Y., Kojima E., Alcaide M.L., Chokekijchai S., Roy B.M., Arnold E., Yarchoan R., Mitsuya H. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2398-2402.
33. Stuhlmann H., Berg P. Homologous recombination of copackaged retrovirus RNAs during reverse transcription. J. Virol. 66:1992;1278-2388.
34. Tudor-Williams G., St Clair M.H., McKinney R.E., Maha M., Walter E., Santacroce S., Mintz M., O'Donnell K., Rudoll T., Vavro C.L., Conner E.M. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet. 339:1992;15-19.
35. Ueno T., Shirasaka T., Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J. Biol. Chem. 270:1995;23605-23611.
36. Yarchoan R., Mitsuya H., Broder S. Strategies for the combination therapy of HIV infection. J. AIDS. 3(suppl 2):1990;S99-S103.
37. Yarchoan R., Lietzau J.A., Ngyen B.Y., Brawley O.W., Pluda J.M., Wyvill K.M., Steinberg S.M., Agbaria R., Mitsuya H., Broder S. A randomized pilot study of alternating and simultaneous regimens of zidovudine (AZT) and didanosine (ddI) in patients with symptomatic human immunodeficiency virus (HIV) infection. J. Infect. Dis. 169:1994;9-17.
38. Zhang D., Caliendo A.M., Eron J.J., Devore K.M., Kaplan J.C., Hirsch M.S., D'Aquila R.T. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:1994;282-287.